Calprotectin in Chronic Prosthetic Joint Infection
Launched by TECHNICAL UNIVERSITY OF MUNICH · Sep 19, 2021
Trial Information
Current as of July 25, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how a protein called calprotectin can help doctors diagnose infections in artificial joints, which can be a serious complication requiring additional surgery. When someone has an infection in their prosthetic joint, the symptoms can be very similar to other issues like loosening or instability of the implant. The researchers believe that measuring the level of calprotectin in the fluid around the joint could make it easier to identify an infection, as higher levels of this protein would suggest an infection is present.
If you're scheduled to have surgery to replace an artificial joint due to infection, loosening, instability, misalignment, or a fracture, you may be eligible to participate in this study. However, if you have a current acute infection in your joint, you would not qualify. Participants will provide joint fluid samples during their surgery, which will help the researchers understand how calprotectin levels differ in infected versus non-infected joints. This could lead to better ways to diagnose prosthetic joint infections in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- * scheduled arthroplasty exchange for any of the following reasons:
- • infection
- • loosening
- • instability
- • malalignment
- • periprosthetic fracture
- Exclusion Criteria:
- • acute prosthetic joint infection
About Technical University Of Munich
The Technical University of Munich (TUM) is a leading research institution in Germany, renowned for its commitment to excellence in education, innovation, and technology transfer. With a strong emphasis on interdisciplinary collaboration, TUM fosters advancements in various fields, including medicine and life sciences. The university actively engages in clinical research, aiming to translate scientific discoveries into practical applications that improve patient outcomes. Through its state-of-the-art facilities and a network of partnerships with hospitals and industry, TUM is dedicated to conducting rigorous clinical trials that adhere to the highest ethical standards and contribute significantly to the advancement of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Munich, Bavaria, Germany
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials